R
Ranjita Misra
Researcher at Sathyabama University
Publications - 22
Citations - 3846
Ranjita Misra is an academic researcher from Sathyabama University. The author has contributed to research in topics: Drug delivery & Cancer. The author has an hindex of 11, co-authored 22 publications receiving 3300 citations. Previous affiliations of Ranjita Misra include Indian Institute of Technology Madras & Nalco Holding Company.
Papers
More filters
Journal ArticleDOI
Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging
TL;DR: A comprehensive review on the potential of nanotechnology in medicine focuses on different nanoparticulate drug-delivery systems including polymeric NPs, ceramic Nps, magnetic NPS, polymeric micelles and dendrimers as well as their applications in therapeutics, diagnostics and imaging.
Journal ArticleDOI
Cancer nanotechnology: application of nanotechnology in cancer therapy.
TL;DR: A review of the approaches of cancer nanotechnology in the advancement of cancer therapy focuses on the target-specific drug therapy and methods for early diagnosis of pathologies.
Journal ArticleDOI
Coformulation of Doxorubicin and Curcumin in Poly(d,l-lactide-co-glycolide) Nanoparticles Suppresses the Development of Multidrug Resistance in K562 Cells
Ranjita Misra,Sanjeeb K. Sahoo +1 more
TL;DR: Combinational therapy by using DOX and CUR, especially when administered in the NP formulation, has enhanced the cytotoxicity in K562 cells by promoting the apoptotic response and has significant promise in the clinical management of intractable diseases, especially leukemia.
Journal ArticleDOI
The mesenchymal stem cell secretome: A new paradigm towards cell-free therapeutic mode in regenerative medicine.
L Praveen Kumar,Sangeetha Kandoi,Ranjita Misra,S. Vijayalakshmi,Kalyanaraman Rajagopal,Rama Shanker Verma +5 more
TL;DR: This review will focus on the accumulating evidence that points to the therapeutic potential of the conditioned medium, both from pre-clinical and clinical studies, and the importance of profiling the conditionedmedium for assessing its potential for cell-free therapy therapy.